Press Release
March 28, 2023
EnteroBiotix Initiates Phase 2 Study
IMPuLSE Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy GLASGOW, United Kingdom | March 28, 2023 – EnteroBiotix Limited (“EBX”),…
We target oncology, neurosciences, rare disease, and antimicrobial resistance. In addition to targeting these disease states with patients in need, we look for biotech and medtech companies dramatically changing how medicine is practiced. We have a particular interest in supporting companies with disruptive technologies in cell and gene therapy, gene editing, and mRNA/RNAi, all technologies.
Kineticos works with companies at all stages of their life cycle, from start-up to commercialization.
IMPuLSE Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy GLASGOW, United Kingdom | March 28, 2023 – EnteroBiotix Limited (“EBX”),…
Kineticos takes an immersive stance with their biotech engagements and investments, working closely in a collaborative effort with key leadership…